Fecal M2-PK in Children with Crohn’s Disease: A Preliminary Report

[1]  D. Turner,et al.  Update of fecal markers of inflammation in inflammatory bowel disease , 2011, Journal of gastroenterology and hepatology.

[2]  A. Griffiths,et al.  Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response , 2010, Gut.

[3]  S. Lewis,et al.  Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers , 2010, Annals of clinical biochemistry.

[4]  S. Lewis,et al.  Fecal dimeric M2‐pyruvate kinase (tumor M2‐PK) in the differential diagnosis of functional and organic bowel disorders , 2009, Inflammatory bowel diseases.

[5]  J. Stockman.  Laboratory Values for Children With Newly Diagnosed Inflammatory Bowel Disease , 2009 .

[6]  A. Day,et al.  Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children , 2008, Inflammatory bowel diseases.

[7]  I. Forgacs,et al.  Fecal M2‐pyruvate kinase (M2‐PK): A novel marker of intestinal inflammation , 2007, Inflammatory bowel diseases.

[8]  K. Herzig,et al.  Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.

[9]  A. Day,et al.  Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.

[10]  N. Afzal,et al.  Inflammatory bowel disease , 2006, Archives of Disease in Childhood.

[11]  H. Brenner,et al.  Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. , 2006, Clinical chemistry.

[12]  A. Michalsen,et al.  Comparison of 4 Neutrophil‐Derived Proteins in Feces As Indicators of Disease Activity in Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[13]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[14]  M. Drews,et al.  Fecal pyruvate kinase (M2-PK): A new predictor for inflammation and severity of pouchitis , 2005, Scandinavian journal of gastroenterology.

[15]  E. Eigenbrodt,et al.  Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer , 2004, British Journal of Cancer.

[16]  S. Ghosh,et al.  Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002 .

[17]  T. Yao.  [Inflammatory bowel diseases]. , 2002, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[18]  I. Arnott,et al.  Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? , 2002, Alimentary pharmacology & therapeutics.

[19]  J T Boyle,et al.  Development and validation of a pediatric Crohn's disease activity index. , 1991, Journal of pediatric gastroenterology and nutrition.